<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02916706</url>
  </required_header>
  <id_info>
    <org_study_id>MP-513-C02</org_study_id>
    <nct_id>NCT02916706</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Teneligliptin in Chinese Patients With Type 2 Diabetes Mellitus</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mitsubishi Tanabe Pharma Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mitsubishi Tanabe Pharma Corporation</source>
  <brief_summary>
    <textblock>
      This study is designed as a prospective, multi-centre, parallel group, double-blind
      randomized, placebo-controlled, phase 3 clinical study to evaluate the efficacy and safety of
      MP-513 (Teneligliptin).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in HbA1c from baseline to week 24</measure>
    <time_frame>baseline and 24 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Teneligliptin 20mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Teneligliptin (20mg once daily) for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Teneligliptin 20mg</intervention_name>
    <arm_group_label>Teneligliptin 20mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A signed and dated informed consent form has been obtained from the subject, in
             accordance with International Conference on Harmonisation guidelines on Good Clinical
             Practice (ICH GCP), before any screening or study related procedures take place.

          -  The subject is aged ≥18 years at signature of the informed consent form.

          -  Hospitalization status: outpatient.

          -  The subject has had a documented diagnosis of type 2 diabetes mellitus for at least 3
             months at the screening visit (Day -28).

          -  The subject is undergoing diet and exercise therapy, and diet and exercise regimen has
             not been changed for at least 8 consecutive weeks at the screening visit (Day -28).
             Subjects who cannot do exercise due to complication are not limited to this criteria.

          -  The subject's glycosylated fraction of haemoglobin(HbA1c) is ≥ 7.0% and &lt; 10.0% at the
             screening visit (Day -28) and on Day -14.

        Exclusion Criteria:

          -  The subject has a history of type 1 diabetes mellitus or a secondary form of diabetes.

          -  The subject has received insulin within 1 year prior to the screening visit (Day -28),
             with the exception of insulin therapy during hospitalization or insulin therapy for
             medical conditions not requiring hospitalization (&lt; 2 weeks' duration).

          -  The subject has received an anti-diabetic drug within 8 weeks prior to the screening
             visit (Day -28).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>General Manager</last_name>
    <role>Study Director</role>
    <affiliation>Mitsubishi Tanabe Pharma Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trials Information Desk</last_name>
    <email>cti-inq-ml@ml.mt-pharma.co.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Investigational center</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 26, 2016</study_first_submitted>
  <study_first_submitted_qc>September 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 27, 2016</study_first_posted>
  <last_update_submitted>October 5, 2017</last_update_submitted>
  <last_update_submitted_qc>October 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

